Building an Enterprise AI Gateway for Pharma: Guardrails, Audit Trails, and Why “Just Use ChatGPT” Isn’t an Answer

Building an Enterprise AI Gateway for Pharma: Guardrails, Audit Trails, and Why “Just Use ChatGPT” Isn’t an Answer

When we started building DnXT Solutions, our vision was clear: to bring cutting-edge technology to life sciences regulatory operations, making complex processes simpler, faster, and more compliant. For years, we’ve delivered on that promise, and frankly, the pace of change in AI today is both exhilarating and, for many in pharma, deeply unsettling. I’ve personally sat across from countless regulatory leaders who see the immense potential of AI – for summarizing vast document sets, classifying submissions, drafting cover letters, or intelligent search – but they’re paralyzed by the compliance risks.

The problem is stark: Regulatory teams want to use AI. They see their colleagues in other functions, or even their friends outside pharma, chatting away with large language models (LLMs) and getting instant insights. The temptation to “just use ChatGPT” or another public AI service for quick tasks is strong. But for anyone in a regulated industry, especially pharma, that’s a non-starter. Sending confidential drug application data, trial subject information, or proprietary formulation details to a third-party API with no audit trail, no PII detection, and absolutely no compliance controls isn’t just risky; it’s a direct path to a regulatory nightmare. It’s a breach waiting to happen, a data leak that could jeopardize drug approvals and patient trust.

On the other end of the spectrum, the alternative often proposed is “build your own LLM from scratch.” For most pharmaceutical companies, this is a multi-million dollar, multi-year endeavor requiring a specialized team that simply isn’t feasible or justifiable. It’s an astronomical investment for a capability that needs to be integrated, not reinvented.

This left a massive void. There was no practical middle ground: no managed, pharmaceutical-grade AI gateway that offered the power of AI while enforcing the stringent compliance controls absolutely necessary for life sciences. We saw this gap, felt the frustration from our clients, and knew we had to build it. That’s why we committed to developing our own enterprise AI gateway – a robust, compliant solution specifically designed for the unique demands of regulatory operations.

The Core Problem: AI in Pharma is a Governance Challenge, Not Just a Technology One

From the moment we started sketching out the architecture for our AI gateway, one truth became abundantly clear: AI in pharma isn’t primarily a technology problem. It’s a governance problem. The question isn’t “can AI do this?” It’s “can AI do this with a full audit trail, PII protection, tenant isolation, and regulatory oversight?” If the answer to the latter is no, then the technology, however brilliant, is useless in our industry.

Our experience has shown us that every pharmaceutical company, regardless of size, will eventually need an AI gateway layer. It’s not a luxury; it’s an inevitability. And critically, building this into your core platform from the ground up is immeasurably better than trying to bolt it on later as an afterthought. Retrofitting compliance and security onto an existing, unmanaged AI pipeline is a costly, error-prone exercise that rarely achieves true regulatory robustness.

“The question isn’t ‘can AI do this?’ It’s ‘can AI do this with a full audit trail, PII protection, tenant isolation, and regulatory oversight?’ If the answer to the latter is no, then the technology, however brilliant, is useless in our industry.”

What We Built: A Compliant Enterprise AI Gateway

At its heart, our AI Gateway service is an intelligent intermediary. It sits between the user (or our platform’s applications) and a diverse ecosystem of LLM providers, including Anthropic, OpenAI, Azure OpenAI, and even customer-specific self-hosted models. This multi-provider routing capability is crucial because no single LLM is a silver bullet. Different tasks require different models, and different data sensitivities demand different deployment environments.

Let me break down the critical components we engineered to ensure pharmaceutical-grade compliance:

1. Multi-Provider Routing & Strategic Model Selection

• The Need: Not all LLMs are created equal. Some excel at speed for quick classifications, others at complex summarization, and some are best suited for highly sensitive data where proprietary models or self-hosted instances are paramount.
• Our Solution: Our gateway intelligently routes requests to the most appropriate LLM. For instance, a fast, cost-effective model might handle document classification, while a more capable, powerful model is reserved for nuanced summarization tasks. And for documents containing highly sensitive PII or proprietary formulation data, the system can be configured to use only self-hosted or strictly controlled private cloud models that never allow data to leave the customer’s dedicated environment. This flexibility is key to balancing performance, cost, and risk.

2. Proactive PII Detection and Redaction

• The Need: This is arguably the most critical layer for pharmaceutical compliance. The risk of inadvertently sending patient identifiers, clinical trial subject data, or confidential drug formulation details to an external LLM is unacceptable.
• Our Solution: We implemented a sophisticated PII detection layer that scans every single request and its associated data before it leaves our system and is sent to an external LLM. If the gateway identifies patient identifiers, trial subject data, proprietary formulation details, or other sensitive information, it takes immediate action. Depending on configuration, it can block the request entirely, redact the sensitive portions, or flag it for human review. This isn’t an optional feature; it’s a fundamental guardrail that ensures data privacy and regulatory adherence.

3. Comprehensive Audit Trails (21 CFR Part 11 Ready)

• The Need: In pharma, if it’s not documented, it didn’t happen. This applies doubly to AI interactions. Regulators need to know exactly what AI was used, by whom, on what data, and what the outcome was.
• Our Solution: Every single AI interaction is meticulously logged. We capture:
  • Who initiated the request.
  • What data was sent to the LLM (including any redactions).
  • Which specific LLM model and version was used.
  • What prompt was given.
  • What response was returned by the LLM.
  • Timestamp and unique transaction ID.

  This isn’t just basic logging; it’s a granular, immutable record designed to be 21 CFR Part 11 compliant, providing a complete, defensible audit trail for every AI-driven decision or output within our ecosystem.

4. Robust Tenant Isolation

• The Need: In a multi-tenant SaaS environment, ensuring that one customer’s data and AI interactions are completely separate and secure from another’s is non-negotiable.
• Our Solution: Our architecture guarantees strict tenant isolation. Customer A’s data, configurations, and AI interactions are logically and physically separated from Customer B’s. This prevents any cross-contamination of data or models and maintains the integrity and confidentiality required by pharmaceutical regulations.

5. Retrieval Augmented Generation (RAG) for Grounded Responses

• The Need: LLMs are powerful but prone to “hallucinations” – generating plausible but factually incorrect information. For regulatory use cases, this is unacceptable. AI responses must be grounded in verified, authoritative documents.
• Our Solution: Our AI Gateway integrates seamlessly with our proprietary search service, which indexes and understands the customer’s actual document corpus. When a user asks a question, the gateway first retrieves relevant, verified information from the customer’s own documents. This retrieved context is then fed to the LLM along with the user’s prompt, ensuring that the AI’s response is accurate, verifiable, and directly supported by the customer’s authoritative data. This significantly reduces hallucinations and increases the trustworthiness of AI-generated content.

The Compliance Framework: Beyond Technology, Into Governance

An enterprise AI gateway for pharmaceutical compliance isn’t just about the code; it’s about the framework that governs its use. We built our system with these principles in mind:

• Role-Based Access Control (RBAC): Not everyone in an organization needs or should have access to every AI capability. Our system allows granular control, defining who can use which AI features, on which document types, and with which models. This ensures that AI is used responsibly and only by authorized personnel.
• Model Governance: We maintain strict control over which models are available for use, whether they are self-hosted or cloud-based, and which types of documents can be sent to external providers. This governance layer allows our clients to define their own risk appetite and enforce it systematically.
• Explainability for AI Decisions: Especially for critical tasks like document classification or risk assessment, it’s not enough for the AI to just give an answer. Our system is designed to show why it made a particular classification or recommendation, referencing specific passages or data points. This explainability is vital for regulatory scrutiny and builds trust in AI-driven processes.

The Hard Decisions We Made

Building something truly useful and compliant always involves tough choices. Here are some of the dilemmas we faced and how we navigated them:

Self-Hosted vs. Cloud LLMs: A Matter of Sovereignty

From day one, we knew we couldn’t take a one-size-fits-all approach. Some global top-20 pharma companies have explicit mandates that certain types of data (e.g., preclinical research, highly sensitive IP) can never, under any circumstances, leave their private cloud or on-premise environments. For these clients, even a private Azure OpenAI instance might not be enough. So, while integrating with leading cloud LLMs was essential for broader adoption and flexibility, we also invested heavily in supporting self-hosted LLMs. This allows customers with the most stringent data sovereignty requirements to still leverage AI, but with their data never leaving their control. It adds complexity to our deployments, but it’s a non-negotiable for true enterprise AI gateway pharmaceutical compliance.

Speed vs. Safety: PII Scanning Latency

Implementing a robust PII detection and redaction layer isn’t free. Scanning documents for sensitive information, especially large ones, adds a measurable amount of latency to every request. There were internal debates about optimizing for speed by potentially making the PII scanning more lightweight or even optional for “less sensitive” tasks. We quickly shut that down. For pharmaceutical data, there’s no such thing as “less sensitive” when it comes to PII or proprietary information. The risk of a breach far outweighs the marginal gain in speed. We optimized the PII scanning to be as efficient as possible, but we accepted that a slight delay was a necessary trade-off for absolute data safety. Safety always wins.

Model Selection: Newer Isn’t Always Better

The LLM landscape is evolving at breakneck speed. New models are released constantly, often boasting higher benchmark scores. The temptation is to always chase the latest and greatest. However, in a regulated environment, stability, consistency, and predictable behavior often matter more than raw benchmark scores. We learned to prioritize models that demonstrate long-term stability, provide consistent outputs for specific tasks, and have robust API support. While we continuously evaluate and integrate newer models, we do so with a cautious, validation-first approach. A model that consistently performs well for a specific regulatory task, even if it’s not the absolute bleeding edge, is often preferable to a newer, more powerful model whose behavior might be less predictable or subject to frequent, unannounced changes.

The Road Ahead

The journey to fully harness AI in pharmaceutical regulatory operations is just beginning. What we’ve built at DnXT Solutions is a foundational layer – an enterprise AI gateway – that addresses the immediate and critical needs for compliance, security, and governance. It’s about empowering regulatory teams to innovate with AI, not just dream about it, by providing the essential guardrails that protect sensitive data and uphold regulatory integrity.

If you’re grappling with how to safely and compliantly integrate AI into your regulatory workflows, you’re not alone. We’ve walked this path, built the solutions, and learned the hard lessons. The future of regulatory operations is undeniably AI-powered, but only if it’s AI that’s secure, auditable, and compliant.